8-K: Zivo Bioscience to be Delisted from Nasdaq, Transitions to OTCQB Market

Zivo Bioscience's common stock and warrants will be delisted from Nasdaq and will continue trading on the OTCQB market.

Summary

• Zivo Bioscience's stock and warrants were suspended from trading on the Nasdaq on November 27, 2023, due to noncompliance with Nasdaq Listing Rule 5550(b)(1).
• On February 13, 2024, Nasdaq announced it would formally delist Zivo's common stock and warrants.
• Since November 27, 2023, the company's common stock has been trading on the OTC Markets Pink Sheets and then transitioned to the OTCQB market tier on January 26, 2024, under the symbol ZIVO.
• The company's warrants have been trading on the OTC Markets Pink Sheets under the symbol ZIVOW since November 27, 2023.

Sentiment

Score: 3

Explanation: The delisting from Nasdaq is a significant negative event, indicating financial or compliance issues. While the company continues to trade on the OTC market, the overall sentiment is negative.

Positives

• The company's stock and warrants continue to trade on the OTC markets, ensuring some level of liquidity for investors.

Negatives

• The delisting from Nasdaq is a negative event for the company, potentially reducing its visibility and investor confidence.
• The company failed to comply with Nasdaq Listing Rule 5550(b)(1), leading to the delisting.

Risks

• Delisting from Nasdaq may lead to decreased trading volume and potentially lower stock prices.
• The company's noncompliance with Nasdaq listing rules raises concerns about its financial health and governance.

Industry Context

Delisting from a major exchange like Nasdaq is generally viewed negatively in the biotech industry, often indicating financial or compliance issues. Companies in this situation typically face challenges in raising capital and maintaining investor confidence.

Comparison to Industry Standards

• Companies that fail to meet Nasdaq's minimum listing requirements often face delisting, which is a common occurrence in the biotech sector, especially for smaller companies with volatile financials.
• Many companies that are delisted from Nasdaq move to the OTC markets, which is a less regulated environment with lower listing standards.
• Compared to companies that maintain their Nasdaq listing, Zivo's delisting suggests a weaker financial position and potential challenges in future growth.

Stakeholder Impact

• Shareholders may experience a decrease in the value of their holdings due to the delisting.
• The company's ability to raise capital may be negatively impacted.
• The delisting may affect the company's reputation and its ability to attract new investors.

Key Dates

Keywords

delisting, Nasdaq, OTCQB, OTC Markets, ZIVO, ZIVOW, stock, warrants, trading, noncompliance